Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Bisindolylmaleimide Ix. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HIPK1 | Q86Z02 | 2/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PRKCA | P17252 | 4/20 | 0.91 |
| ▸ | PRKCB | P05771 | 3/20 | 0.91 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.91 |
| ▸ | PIM1 | P11309 | 3/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisindolylmaleimide Ix SCHEMBL29381390 | 1.00 | MEN1 (1.00) | MEN1TP53CYP3A4MAPTALOX15 | |
| SCHEMBL8166772 | 0.97 | MEN1 (0.95) | MEN1TP53CYP3A4MAPTALOX15 | |
| SCHEMBL8161675 | 0.96 | MEN1 (0.93) | MEN1TP53CYP3A4MAPTALOX15 | |
| Bisindolylmaleimide Ix SCHEMBL29370657 | 0.95 | PRKCA (1.00) | MEN1TP53CYP3A4MAPTALOX15 | |
| Bisindolylmaleimide Ix SCHEMBL1567017 | 0.95 | PRKCA (1.00) | MEN1TP53CYP3A4MAPTALOX15 | |
| SCHEMBL8154377 | 0.94 | MEN1 (0.89) | MEN1TP53CYP3A4MAPTALOX15 | |
| SCHEMBL8160685 | 0.87 | MEN1 (0.77) | MEN1TP53CYP3A4MAPTALOX15 | |
| SCHEMBL15600252 | 0.86 | PIM1 (0.83) | MEN1TP53CYP3A4MAPTALOX15 | |
| SCHEMBL18134615 | 0.85 | PIM1 (0.81) | MEN1TP53CYP3A4MAPTALOX15 | |
| SCHEMBL8161316 | 0.85 | CAMK2D (0.87) | MEN1TP53CYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070196514-A1 | Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors | UNIVERSITY OF KANSAS MEDICAL CENTER | 2007-08-23 | — | — | US | claimed |
| US-20040115801-A1 | Model epithelial cell cultures | KINETANA GROUP INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004018657-A1 | MODEL EPITHELIAL CELL CULTURES | KINETANA GROUP INC. (CA) | 2004-03-04 | — | — | WO | claimed |
| WO-2023149495-A1 | PRODUCTION METHOD FOR INDUCED PLURIPOTENT STEM CELLS | 国立研究開発法人理化学研究所 | 2023-08-10 | — | — | WO | disclosed |
| US-20200289566-A1 | COMPOSITIONS FOR IMPROVING CAR-T CELL FUNCTIONALITY AND USE THEREOF | PROSPECT CHARTERCARE RWMC LLC D/B/A ROGER WILLIAMS MEDICAL CENTER (US) | 2020-09-17 | — | — | US | disclosed |
| US-9987280-B2 | SIRT1 inhibitors and stem cell rejuvenation | CITY OF HOPE (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170216360-A1 | METHODS AND COMPOSITIONS FOR IMPROVING HOMING OF CELLS INCLUDING MESENCHYMAL STEM CELLS | THE GENERAL HOSPITAL CORPORATION | 2017-08-03 | — | — | US | disclosed |
| US-20160151379-A1 | COMBINATION THERAPIES FOR MALARIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-02 | — | — | US | disclosed |
| US-20150044184-A1 | SIRT1 INHIBITORS AND STEM CELL REJUVENATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| WO-2015006753-A2 | THERAPIES FOR DISEASES CAUSED BY ARTHROPOD-BORNE PARASITES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006752-A1 | COMBINATION THERAPIES FOR MALARIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20130059385-A1 | METHODS OF GENERATING PLURIPOTENT STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011109015-A1 | IMPROVED METHODS OF GENERATING PLURIPOTENT STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20070196514-A1 | Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors | UNIVERSITY OF KANSAS MEDICAL CENTER | 2007-08-23 | — | — | US | disclosed |
| US-20040115801-A1 | Model epithelial cell cultures | KINETANA GROUP INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040115801-A1 | Model epithelial cell cultures | KINETANA GROUP INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004018657-A1 | MODEL EPITHELIAL CELL CULTURES | KINETANA GROUP INC. (CA) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018657-A1 | MODEL EPITHELIAL CELL CULTURES | KINETANA GROUP INC. (CA) | 2004-03-04 | — | — | WO | disclosed |
| US-RE36736-E | Substituted pyrroles | HOFFMAN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | disclosed |
| US-5057614-A | Antiinflammatory, immunology, bronchodilator agents, cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 1991-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216360-A1 | METHODS AND COMPOSITIONS FOR IMPROVING HOMING OF CELLS INCLUDING MESENCHYMAL STEM CELLS | CXCL12, VCAM1, ICAM1 | MEN1 4026/4885TP53 2104/4885CYP3A4 4872/4885 |
| US-20150044184-A1 | SIRT1 INHIBITORS AND STEM CELL REJUVENATION | SIRT1, SIRT2, SIRT3 | MEN1 498/4885TP53 177/4885CYP3A4 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.